Drug Profile

Research programme: transdermal parathyroid hormone analogue - Altea Therapeutics

Latest Information Update: 15 Nov 2012

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Altea Therapeutics
Class Peptide hormones
Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

12 Nov 2012 Nitto Denko acquires all assets of Altea Therapeutics
09 Dec 2011 Discontinued - Preclinical for Osteoporosis in USA (Transdermal)
07 Jul 2008 Preclinical trials in Osteoporosis in USA (Transdermal)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com